Comparative renal risk of long-term use of beta-lactams in combination with vancomycin across the continuum of care

Lauren M. Dolly,Christina G. Rivera,Kelsey L. Jensen,Kristin C. Mara,Diana J. Schreier,Abinash Virk,Kellie N. Arensman Hannan

DOI: https://doi.org/10.1177/20499361231189589

2023-01-01

Therapeutic Advances in Infectious Disease

Abstract:Background: Data are controversial regarding nephrotoxicity risk with vancomycin plus piperacillin–tazobactam (VPT) compared to vancomycin alone or in combination with other beta-lactams (BLs) in acute care use. Furthermore, data are lacking on the incidence of acute kidney injury (AKI) with long-term use of VPT including outpatient parenteral antimicrobial therapy (OPAT). Methods: This retrospective study included 826 adult patients on an intravenous vancomycin plus BL for ⩾2 weeks, including cefepime, piperacillin/tazobactam, ertapenem, or meropenem, from August 2017 to January 2022. The primary outcome was incidence of AKI. Univariate and multivariable Cox proportional hazard regression analyses were conducted to adjust for confounding variables. A secondary analysis based on the propensity score (PS)-matched cohort was performed. Results: AKI occurred in 14.4% of patients in the VPT group ( n = 15/104) compared to 5.5% in the other BL group ( n = 40/722) ( p 2 weeks, including in the OPAT setting, even when no renal dysfunction is observed during the initial week of combination therapy.